Creative Medical secures FDA Fast Track designation for CELZ-201-DDT

Creative Medical (CELZ) Technology announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease, DDD, a major cause of chronic lower back pain and disability. “Fast Track designation from the FDA is both a validation of our scientific approach and a catalyst for value creation,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “Lower back pain from degenerative disc disease remains a leading cause of disability worldwide, and the opioid crisis underscores the urgent need for new, non-addictive solutions. As we near final enrollment in our FDA cleared clinical trial, we believe CELZ-201-DDT has the potential to transform patient care while driving shareholder value through accelerated development timelines.”